J Korean Ophthalmol Soc.  2013 Feb;54(2):387-390. 10.3341/jkos.2013.54.2.387.

Temporary Accommodation Difficulties after Botulinum Toxin Type B Injection for the Treatment of Hyperhidrosis

Affiliations
  • 1Department of Ophthalmology, Jeju National University School of Medicine, Jeju, Korea. amario@naver.com

Abstract

PURPOSE
To report a case of temporary accommodation difficulties after botulinum toxin injections for the treatment of palmar and plantar hyperhidrosis.
CASE SUMMARY
A 27-year-old woman presented with difficulties performing near work that had begun 1 week prior. She underwent injections of botulinum toxin type B (Myobloc(R)) for the treatment of both palmar and plantar hyperhidrosis 3 weeks earlier. The patient had subdermal injections of 3000 MU (mouse unit) of Myobloc(R) on each palm and sole. On manifest refraction, the patient was emmetropic. Near point of accommodation was 32 cm in the right eye and 25 cm in the left eye, near point of convergence was 10 cm, and the monocular accommodative power measured with minus lenses was 1.5 diopter (D) in the right eye and 2.0 D in the left eye. After 3 weeks, accommodation difficulties were completely resolved and hyperhidrosis symptoms did not recur.
CONCLUSIONS
Ophthalmologic adverse effects related to the autonomic nervous system such as accommodation difficulties may occur with injections of botulinum toxin type B for the treatment of hyperhidrosis. These symptoms should be explained carefully to the patient before the botulinum toxin injection procedure.

Keyword

Accommodation difficulty; Adverse effect; Botulinum toxin type B; Hyperhidrosis; Myobloc

MeSH Terms

Autonomic Nervous System
Botulinum Toxins
Eye
Female
Humans
Hyperhidrosis
Botulinum Toxins

Reference

References

1. Atkins JL, Butler PE. Hyperhidrosis: a review of current management. Plast Reconstr Surg. 2002; 110:222–8.
Article
2. Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004; 51:274–86.
Article
3. Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyper-hidrosis: results from a national survey. J Am Acad Dermatol. 2004; 51:241–8.
Article
4. Heckmann M, Ceballos-Baumann AO, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med. 2001; 344:488–93.
Article
5. Adar R, Kurchin A, Zweig A, Mozes M. Palmar hyperhidrosis and its surgical treatment: a report of 100 cases. Ann Surg. 1977; 186:34–41.
6. Lee JK, Kim JH, Kwak HJ, et al. Uniportal endoscopic thoracic sympathicotomy for primary hyperhidrosis. J Korean Neurosurg Soc. 2002; 31:16–20.
7. Glaser DA. The use of botulinum toxins to treat hyperhidrosis and gustatory sweating syndrome. Neurotox Res. 2006; 9:173–7.
Article
8. Frasson E, Brigo F, Acler M, et al. Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months. Arch Dermatol. 2011; 147:122–3.
Article
9. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol. 2003; 49:34–8.
Article
10. Kern U, Kohl M, Seifert U, Schlereth T. Botulinum toxin type B in the treatment of residual limb hyperhidrosis for lower limb amputees: a pilot study. Am J Phys Med Rehabil. 2011; 90:321–9.
11. Tintner R, Gross R, Winzer UF, et al. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005; 65:765–7.
Article
12. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987; 2:237–54.
Article
13. Dressler D. Clinical applications of botulinum toxin. Curr Opin Microbiol. 2012; 15:325–36.
Article
14. Girlanda P, Vita G, Nicolosi C, et al. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry. 1992; 55:844–5.
Article
15. Lagalla G, Millevolte M, Capecci M, et al. Long-lasting benefits of botulium toxin type B in Parkinson's disease- related drooling. J Neurol. 2009; 256:563–7.
16. Dressler D, Adib Saberi F, Benecke R.Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol. 2002; 249:1729–32.
Article
17. Von Noorden GK, Campos EC. Binocular vision and ocular motility : theory and management of strabismus. 6th ed. St. Louis: Mosby;2002. p. 85–6.
18. Duane A. Studies in monocular and binocular accommodation, with their clinical application. Trans Am Ophthalmol Soc. 1922; 20:132–57.
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr